Last week, the European Medicines Agency (EMA) released a report describing its contributions to science, medicines, and health for the year 2017.
Last week, the European Medicines Agency (EMA) released a report describing its contributions to science, medicines, and health for the year 2017.
Last year, the EMA recommended a total of 92 medicines for marketing authorization and of these approvals, 35 contained a new active substance.
The number of applications for biosimilar medicines continues to grow year over year, with 17 applications received by the EMA in 2017, compared with 14 in 2016. The EMA also reported that this is the highest number of applications it has received to date in a single year. To date, the Committee for Medicinal Products for Human Use has given positive opinions for 28 biosimilars in the European Union.
Furthermore, the EMA and the European Commission (EC) released an information guide for healthcare professionals on biosimilar medicines in May 2017. The objective of the guide was to provide healthcare professionals with information on both the science and the regulation of biosimilar drugs.
“Promoting innovation and research in medicine development so that patients can benefit from much-needed safe, high-quality and effective medicines is a key priority for the Agency,” said the EMA in its report.
In the United States, the FDA more than doubled the number of drugs it approved in 2017, with 46 novel medicines receiving the green light compared with the year prior. However, it is important to note that the US drug approval tally for 2017 does not include the first of a new wave of cell and gene therapies from companies Novartis, Gilead Sciences, and Spark Therapeutics, which all had drug approvals in 2017 under a separate category.
Over the entire span of the biosimilar approval pathway’s use in the United States, the FDA has approved only 9 biosimilar therapies, with no approvals to date in 2018. In fact, the FDA has issued 4 Complete Response Letters (CRLs) in 2018: Celltrion received CRLs for both its proposed rituximab and trastuzumab biosimilars; Sandoz for its proposed rituximab biosimilar; and Pfizer for its proposed trastuzumab biosimilar.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.